Argininosuccinate Synthase 1 is a Metabolic Regulator of Colorectal Cancer Pathogenicity
Citations Over TimeTop 22% of 2017 papers
Abstract
Like many cancer types, colorectal cancers have dysregulated metabolism that promotes their pathogenic features. In this study, we used the activity-based protein profiling chemoproteomic platform to profile cysteine-reactive metabolic enzymes that are upregulated in primary human colorectal tumors. We identified argininosuccinate synthase 1 (ASS1) as an upregulated target in primary human colorectal tumors and show that pharmacological inhibition or genetic ablation of ASS1 impairs colorectal cancer pathogenicity. Using metabolomic profiling, we show that ASS1 inhibition leads to reductions in the levels of oncogenic metabolite fumarate, leading to impairments in glycolytic metabolism that supports colorectal cancer cell pathogenicity. We show here that ASS1 inhibitors may represent a novel therapeutic approach for attenuating colorectal cancer through compromising critical metabolic and metabolite signaling pathways and demonstrate the utility of coupling chemoproteomic and metabolomic strategies to map novel metabolic regulators of cancer.
Related Papers
- Argininosuccinate synthase: at the center of arginine metabolism.(2011)
- → Argininosuccinate synthetase activity in cultured human lymphocytes(1977)23 cited
- → Modulation of intestinal urea cycle by dietary spermine in suckling rat(2005)2 cited
- → Qualitative Abnormality of Liver Argininosuccinate Synthetase in a Patient with Citrullinemia(1982)5 cited